MUFG Americas Holdings Corp Sells 14,466 Shares of Merck & Co., Inc. (MRK)

MUFG Americas Holdings Corp reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 3.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 445,375 shares of the company’s stock after selling 14,466 shares during the period. Merck & Co., Inc. makes up 0.8% of MUFG Americas Holdings Corp’s portfolio, making the stock its 29th biggest position. MUFG Americas Holdings Corp’s holdings in Merck & Co., Inc. were worth $27,034,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Somerset Group LLC purchased a new position in Merck & Co., Inc. in the second quarter worth about $219,000. Oarsman Capital Inc. purchased a new position in Merck & Co., Inc. in the second quarter worth about $207,000. Riverhead Capital Management LLC boosted its position in Merck & Co., Inc. by 21.7% in the second quarter. Riverhead Capital Management LLC now owns 89,370 shares of the company’s stock worth $5,425,000 after purchasing an additional 15,930 shares during the last quarter. Tyers Asset Management LLC boosted its position in Merck & Co., Inc. by 35.7% in the second quarter. Tyers Asset Management LLC now owns 98,672 shares of the company’s stock worth $5,989,000 after purchasing an additional 25,984 shares during the last quarter. Finally, Meadow Creek Investment Management LLC boosted its position in Merck & Co., Inc. by 48.3% in the second quarter. Meadow Creek Investment Management LLC now owns 56,384 shares of the company’s stock worth $3,423,000 after purchasing an additional 18,352 shares during the last quarter. 72.18% of the stock is currently owned by hedge funds and other institutional investors.

NYSE MRK opened at $71.46 on Tuesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $72.42. The stock has a market capitalization of $191.27 billion, a PE ratio of 17.95, a P/E/G ratio of 2.22 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $1.03 by $0.03. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The firm had revenue of $10.47 billion for the quarter, compared to the consensus estimate of $10.28 billion. During the same quarter last year, the company earned $1.01 earnings per share. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. On average, equities analysts predict that Merck & Co., Inc. will post 4.27 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 5th. Stockholders of record on Monday, September 17th were paid a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend was Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 48.24%.

In other news, Chairman Kenneth C. Frazier sold 228,091 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the transaction, the chairman now owns 938,788 shares of the company’s stock, valued at $61,021,220. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Rita A. Karachun sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $65.01, for a total value of $325,050.00. The disclosure for this sale can be found here. Insiders sold 929,360 shares of company stock worth $64,370,599 in the last ninety days. Corporate insiders own 0.32% of the company’s stock.

MRK has been the topic of several research reports. Morgan Stanley set a $74.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Thursday, August 23rd. SunTrust Banks reissued a “buy” rating and issued a $77.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. Barclays raised their target price on Merck & Co., Inc. from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, September 7th. Jefferies Financial Group reissued a “hold” rating and issued a $59.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 15th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $68.61.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: Technical Analysis

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply